Study Evaluating Enbrel (Etanercept) in Adult Patients With Plaque Psoriasis

The purpose of this study is to investigate the incidences of adverse events for patients with plaque psoriasis treated with Enbrel under usual care settings.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Plaque Psoriasis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Pfizer Investigational Site, Munich, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Proven diagnosis of Plaque Psoriasis

Exclusion criteria

Contraindications according to SmPC of Enbrel

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

Observational Study With Enbrel (Etanercept) in Adult Patients With Plaque Psoriasis

Important dates

Study start: 2005
Primary completion: 2009
Study completion: 2009
First posted: Sep 27, 2005
Registry last updated: Mar 21, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed